
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is a commercial-stage biopharma with a strong portfolio of royalty healthcare assets, including two new launches for Zevtera in S. aureus bacteremia and potentially zoliflodacinin in uncomplicated gonorrhea. The company's growing IST business, with products such as Giapreza and Xacduro leading the way, has performed well and is expected to continue on a healthy growth trajectory. These, combined with the company's steady stream of royalties from GSK and strategic investments, make it an attractive investment opportunity.
Bears say
Innoviva is a healthcare company diversified across three core business segments with their primary source of revenue coming from GSK-partnered assets. However, with declines in forecasted revenue for key products such as Relvar/Breo/Ellipta and Anoro, as well as a recent launch of Nortiva Bio, which may take time to drive meaningful revenue, there are concerns about the company's financial performance and overall valuation. In addition, their strategic investment in Armata Pharmaceuticals may face challenges in gaining market acceptance and generating significant revenue.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares